author-photo

Gabriele Elser

11

Papers

248

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (41)
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

2017 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (68)
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

2016 BMC Medical Ethics
Show All
- Source
- Cite
- Save
Citations (1)
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

2013 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (14)
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)

2006 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Erratum: The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial (Lancet (2003) 361 (2099-106))

2003 The Lancet
Show All
- Source
- Cite
- Save
Citations (66)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (vol 361, pg 2099, 2003)

2003 The Lancet
Show All
- Source
- Cite
- Save
Citations (4)